120 related articles for article (PubMed ID: 1324061)
1. Studies on the cardiac actions of flosequinan in vitro.
Gristwood RW; Beleta J; Bou J; Cardelús I; Fernández AG; Llenas J; Berga P
Br J Pharmacol; 1992 Apr; 105(4):985-91. PubMed ID: 1324061
[TBL] [Abstract][Full Text] [Related]
2. Actions of the novel vasodilator, flosequinan, in isolated ventricular cardiomyocytes.
Kelso EJ; McDermott BJ; Silke B
J Cardiovasc Pharmacol; 1995 Mar; 25(3):376-86. PubMed ID: 7769801
[TBL] [Abstract][Full Text] [Related]
3. Incomplete reversal of beta-adrenoceptor desensitization in human and guinea-pig cardiomyocytes by cyclic nucleotide phosphodiesterase inhibitors.
Wynne DG; Poole-Wilson PA; Harding SE
Br J Pharmacol; 1993 Aug; 109(4):1071-8. PubMed ID: 7691363
[TBL] [Abstract][Full Text] [Related]
4. Involvement of rolipram-sensitive cyclic AMP phosphodiesterase in the regulation of cardiac contraction.
Muller B; Lugnier C; Stoclet JC
J Cardiovasc Pharmacol; 1990 Nov; 16(5):796-803. PubMed ID: 1703603
[TBL] [Abstract][Full Text] [Related]
5. The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Implications for the mechanism of action of selective phosphodiesterase inhibitors.
Reeves ML; Leigh BK; England PJ
Biochem J; 1987 Jan; 241(2):535-41. PubMed ID: 3036066
[TBL] [Abstract][Full Text] [Related]
6. Functional and biochemical evidence for diazepam as a cyclic nucleotide phosphodiesterase type 4 inhibitor.
Collado MC; Beleta J; Martinez E; Miralpeix M; Domènech T; Palacios JM; Hernández J
Br J Pharmacol; 1998 Mar; 123(6):1047-54. PubMed ID: 9559885
[TBL] [Abstract][Full Text] [Related]
7. Differential inotropic effects of flosequinan in ventricular muscle from normal ferrets versus patients with end-stage heart failure.
Perreault CL; Hague NL; Loh E; Hunneyball IM; Sim MF; Morgan JP
Br J Pharmacol; 1992 Jul; 106(3):511-6. PubMed ID: 1324072
[TBL] [Abstract][Full Text] [Related]
8. Effects of SK&F 94120, an inhibitor of cyclic nucleotide phosphodiesterase type III, on human platelets.
Simpson AW; Reeves ML; Rink TJ
Biochem Pharmacol; 1988 Jun; 37(12):2315-20. PubMed ID: 2455518
[TBL] [Abstract][Full Text] [Related]
9. Effect of flosequinan upon isoenzymes of phosphodiesterase from guinea-pig cardiac and vascular smooth muscle.
Frodsham G; Jones RB
Eur J Pharmacol; 1992 Feb; 211(3):383-91. PubMed ID: 1319914
[TBL] [Abstract][Full Text] [Related]
10. Relationship between inotropic activity and phosphodiesterase inhibition for flosequinan and milrinone.
Weishaar RE; Kirker ML; Wallace AM; Ferraris VA; Britton LW; Sim MF
Eur J Pharmacol; 1993 Jun; 236(3):363-6. PubMed ID: 8395383
[TBL] [Abstract][Full Text] [Related]
11. Characterization of ORG 20241, a combined phosphodiesterase IV/III cyclic nucleotide phosphodiesterase inhibitor for asthma.
Nicholson CD; Shahid M; Bruin J; Barron E; Spiers I; de Boer J; van Amsterdam RG; Zaagsma J; Kelly JJ; Dent G
J Pharmacol Exp Ther; 1995 Aug; 274(2):678-87. PubMed ID: 7636728
[TBL] [Abstract][Full Text] [Related]
12. Effects of a cardiotonic quinolinone derivative Y-20487 on the isoproterenol-induced positive inotropic action and cyclic AMP accumulation in rat ventricular myocardium: comparison with rolipram, Ro 20-1724, milrinone, and isobutylmethylxanthine.
Katano Y; Endoh M
J Cardiovasc Pharmacol; 1992; 20(5):715-22. PubMed ID: 1280732
[TBL] [Abstract][Full Text] [Related]
13. Implication of cyclic AMP in the positive inotropic effects of cyclic GMP-inhibited cyclic AMP phosphodiesterase inhibitors on guinea pig isolated left atria.
Muller B; Lugnier C; Stoclet JC
J Cardiovasc Pharmacol; 1990 Mar; 15(3):444-51. PubMed ID: 1691369
[TBL] [Abstract][Full Text] [Related]
14. Positive inotropic and hemodynamic properties of flosequinan, a new vasodilator, and a sulfone metabolite.
Falotico R; Haertlein BJ; Lakas-Weiss CS; Salata JJ; Tobia AJ
J Cardiovasc Pharmacol; 1989 Sep; 14(3):412-8. PubMed ID: 2476620
[TBL] [Abstract][Full Text] [Related]
15. Analysis of responses to a selective phosphodiesterase III inhibitor, SK&F 94120, on isolated myocardium, including human ventricular myocardium from "end-stage" failure patients.
Gristwood RW; English TA; Wallwork J; Sampford KA; Owen DA
J Cardiovasc Pharmacol; 1987 Jun; 9(6):719-27. PubMed ID: 2442540
[TBL] [Abstract][Full Text] [Related]
16. Effect of flosequinan (BTS 49465) on myocardial oxygen consumption.
Greenberg S; Touhey B; Paul J
Am Heart J; 1990 Jun; 119(6):1355-66. PubMed ID: 2353621
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological and biochemical effects of the cardiotonic agent Org10325 in isolated cardiac and vascular tissue preparations.
Shahid M; Martorana MG; Cottney JE; Marshall RJ
Br J Pharmacol; 1990 Aug; 100(4):735-42. PubMed ID: 2169938
[TBL] [Abstract][Full Text] [Related]
18. Positive inotropy contributes to the hemodynamic mechanism of action of flosequinan (BTS 49465) in the intact dog.
Greenberg S; Touhey B
J Cardiovasc Pharmacol; 1990 Jun; 15(6):900-10. PubMed ID: 1694912
[TBL] [Abstract][Full Text] [Related]
19. Positive inotropic activity of 5-amino-6-cyano-1,3-dimethyl-1,2,3,4-tetrahydropyrido[2,3-d]pyrim idine-2,4-dione in cardiac muscle from guinea-pig and man. Part 6: Compounds with positive inotropic activity.
Heber D; Heers C; Ravens U
Pharmazie; 1993 Jul; 48(7):537-41. PubMed ID: 7692456
[TBL] [Abstract][Full Text] [Related]
20. Inotropic and chronotropic effects of 4-(4'-n-butylaniline)-7,8- dimethoxy-5H-pyrimido[5,4-b]indole in guinea-pig atria.
Castiella E; Frechilla D; Lasheras B; Cenarruzabeitia E; Martínez de Irujo JJ; Alberdi E; Santiago E; Monge A; Villanueva A; Martinez FJ
J Pharm Pharmacol; 1995 Jul; 47(7):601-7. PubMed ID: 8568629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
